Abstract library

14 results for "sst2".
#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Eleonora Vitali
Keywords: FLNA, SST2, GEP-NET
#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MSc Marije J Veenstra
Keywords: GEP-NET, sst2, epigenetics
#1118 Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem
Keywords: sst2a
#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Marije Jildau Veenstra
Keywords: NET, sst2, epidrug, signaling
#143 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig
#447 SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)
Introduction: The somatostatin receptor subtype sst2 is largely expressed on neuroendocrine tumors. However, current clinical studies indicate that the subtypes sst1, 3, 5 are of substantial relevance as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Melpomeni Fani
Authors: Fani M, Braun F, Mann A, Kiewer A, ...
Keywords: SOM230, Ga-68, PET imaging
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
Authors: Schmid H A, Chiara L, Nuciforo P, ...
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Conference:
Category: Clinical
Presenting Author: Antongiulio Faggiano
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.